My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

AbbVie (NY:ABBV)

214.35 -0.67 (-0.31%)

Official Closing Price Updated: 7:00 PM EST, Jan 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

92 93 Next >

3 Dividend Kings Down 11% You’ll Regret Not Buying on the Dip ↗

April 22, 2024

These dividend stocks have proved time and again why they're the cream of the crop and will rise to the top once more.

Via InvestorPlace

Why I Keep Buying This Ultra-High-Yielding ETF for Passive Income ↗

April 20, 2024

The JPMorgan Equity Premium Income ETF produces a lucrative monthly passive income stream.

Via The Motley Fool

Topics ETFs

These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher? ↗

April 19, 2024

Small-cap stocks have been the market laggards but these standouts showed how to beat even top-tier tech names at their own game.

Via InvestorPlace

The Bad News Heading Into AbbVie's First-Quarter Earnings Report ↗

April 19, 2024

AbbVie is working against numerous biosimilar versions of Humira. But one has "stepped up dramatically."

Via Investor's Business Daily

Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study ↗

April 18, 2024

Discover toplines results of Cerevel Therapeutics' Phase 3 TEMPO-3 trial for tavapadon in Parkinson's disease treatment. Statistically significant efficacy and safety findings were revealed.

Via Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today ↗

April 17, 2024

Via Benzinga

AbbVie's Options Frenzy: What You Need to Know ↗

April 15, 2024

Via Benzinga

Is AbbVie a Millionaire Maker? ↗

April 14, 2024

Everything is going according to plan, and more growth is on the way.

Via The Motley Fool

Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week ↗

April 21, 2024

Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.

Via Benzinga

Is Your Botox Real Or Fake? Counterfeit Boxes Circulate For Widely Used Antiwrinkle Treatment, CDC And FDA Investigate Harmful Reactions ↗

April 17, 2024

Be cautious of counterfeit Botox for cosmetic use. FDA warns of adverse reactions in multiple states. Symptoms include vision issues, difficulty breathing, and weakness. Ensure authenticity before...

Via Benzinga

Powell And The Great Indecision ↗

April 16, 2024

In today’s presser, Powell basically said what he typically says. Higher for longer but maybe not as risks remain to the economy while inflation is too sticky.

Via Talk Markets

Topics Economy

Steady Income, Steady Growth: 7 Blue-Chip Dividend Stocks to Buy Now ↗

April 16, 2024

With an already tense situation becoming even more troubling, now’s the time to consider blue-chip dividend stocks to buy.

Via InvestorPlace

Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades ↗

April 16, 2024

Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction.

Via Benzinga

Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug ↗

April 15, 2024

The company was testing a potential treatment for schizophrenia in rabbits, but found a notable side effect.

Via Investor's Business Daily

Smart Money Is Betting Big In ABBV Options ↗

April 12, 2024

Via Benzinga

AbbVie Unusual Options Activity For April 05 ↗

April 05, 2024

Via Benzinga

Smart Money Is Betting Big In ABBV Options ↗

April 04, 2024

Via Benzinga

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors

April 12, 2024

From Glancy Prongay & Murray LLP

Via Business Wire

What's Going On AbbVie Stock On Friday? ↗

April 12, 2024

AbbVie releases interim analysis on atogepant, an oral migraine prevention drug. Key findings show significant reductions in migraine days and consistent safety profile. Atogepant, known as Qulipta...

Via Benzinga

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors

April 12, 2024

From Law Offices of Howard G. Smith

Via Business Wire

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024 ↗

April 11, 2024

In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024.

Via InvestorPlace

The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today ↗

April 11, 2024

Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.

Via InvestorPlace

Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says ↗

April 10, 2024

Advances in presbyopia treatment with LENZ Therapeutics' LNZ100. Clinically proven to enhance near-vision for up to 10 hours, it offers a promising alternative to reading glasses. Analysts predict a...

Via Benzinga

The Law Offices of Frank R. Cruz Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors

April 10, 2024

From The Law Offices of Frank R. Cruz

Via Business Wire

3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade ↗

April 09, 2024

Income-seeking investors can look forward to steady payout raises from these pharma stocks.

Via The Motley Fool

3 No-Brainer Dividend Stocks to Buy in April ↗

April 06, 2024

Income investors will find a lot to like about these stocks.

Via The Motley Fool

Passive Income Perfection: 7 Dividend Stocks to Generate $50,000 Per Year ↗

April 04, 2024

These seven dividend stocks provide a base for $50,000 in income per year for dedicated investors with patience.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

April 03, 2024

Via Benzinga

FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape ↗

April 03, 2024

FibroGen reveals Phase 1 results for FG-3246 for metastatic castration-resistant prostate cancer. Promising efficacy metrics and plans for enhanced therapeutic strategies signal potential advancements...

Via Benzinga

The 3 Best Stocks to Buy in April 2024 ↗

April 02, 2024

With market dynamics shifting in the wind, concerned investors may want to target these ideas for best stocks to buy in April.

Via InvestorPlace

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

92 93 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.